Titlebook: Innovation Systems in Small Catching-Up Economies; New Perspectives on Elias G. Carayannis,Urmas Varblane,Tõnu Roolaht Book 2012 Springer

floaters

Maaja Vadi,Harald Lepiska wide geographic area and using heterogeneous resources. Current implementations allow the definition and controlled execution of complex and long lived business processes as the basis for an enterprise-wide collaborative system but, in most cases, the autonomy of the users is greatly restricted du

顽固

available extend the potential for realism of these exercises. In addition, with the use of hypermedia methodologies, it is now possible to link components of a clinical case — e.g., the tests, the images (or sounds or tracings) of the actual results, or the textual descriptions of findings — with o

继而发生

Tiiu Paas,Helen Poltimäefollow-up, to store medical knowledge and to provide facilities for decision making at the level either of the individual patient or of the population followed up. An integrated approach, progressively implemented in the ARTEMIS system since 1975, is described for the computerized management of hype

软膏

Jaan Masso,Priit Vahterfollow-up, to store medical knowledge and to provide facilities for decision making at the level either of the individual patient or of the population followed up. An integrated approach, progressively implemented in the ARTEMIS system since 1975, is described for the computerized management of hype

harbinger

Hilmar Þór Hilmarsson Ph.D.vention coding system as well as the recording of essential patient administrative and medical information. The aim of the program is to improve patient care and research, stimulate study projects between cooperating centers, and enhance the efficient management of departmental resources. The coding

extinct

Invertebrate

transient-pain

Jaan Masso,Tõnu Roolaht,Urmas Varblanedies are usually not able to provide a full picture of the benefit-risk-profile of a new drug for several reasons which increases the likelihood that adverse drug reactions will occur after marketing approval that were not observed during phase III of clinical development. The knowledge gap regardin

resistant

Ingenuity